-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
KPV 10mg is a short research peptide studied in relation to alpha-MSH-derived tripeptide research, melanocortin-related pathway models, cytokine signalling, epithelial barrier research, inflammatory pathway models and cellular stress pathway studies.
KPV stands for Lys-Pro-Val, meaning the peptide is made from lysine, proline and valine. PubChem lists MSH 11-13, commonly associated with KPV, with the molecular formula C16H30N4O4.
This product is supplied for laboratory research use only. It is not a medicine, supplement, gut health product, anti-inflammatory product, autoimmune product, skin product, wound-healing product, recovery product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | KPV |
| Full sequence name | Lysine-Proline-Valine |
| Common research names | KPV, Lys-Pro-Val, MSH 11-13, alpha-MSH C-terminal tripeptide |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Inflammatory Pathway Research / Melanocortin-Related Research |
| Common research interest | Alpha-MSH-related signalling, cytokine pathway models, epithelial barrier research and inflammatory pathway studies |
| Peptide type | Tripeptide |
| Amino acid sequence | Lys-Pro-Val |
| Molecular formula | C16H30N4O4 for MSH 11-13 |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, gut health, inflammation, autoimmune support, skin use or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Lysine | Amino acid component | Forms the “K” in KPV |
| Proline | Amino acid component | Forms the “P” in KPV |
| Valine | Amino acid component | Forms the “V” in KPV |
| KPV sequence | Tripeptide | Studied as the C-terminal tripeptide sequence linked to alpha-MSH pathway research |
| Alpha-MSH context | Parent peptide research context | KPV is commonly discussed as the C-terminal tripeptide of alpha-MSH |
| Melanocortin-related pathway context | Receptor and inflammatory signalling research | Used in pathway models involving cytokine, epithelial and inflammatory signalling |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Product identity, sequence, purity, salt form, acetate status and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. Researchers should not rely on product name alone when confirming peptide identity.
KPV is studied as a short alpha-MSH-related tripeptide. Alpha-MSH-related peptide research is commonly discussed in relation to melanocortin signalling, cytokine pathways, inflammatory pathway models and immune-cell signalling.
A PubMed Central review notes that much of the anti-inflammatory activity discussed for alpha-MSH-related research can be attributed to its C-terminal tripeptide KPV. This should be understood as research literature context only, not as a claim that a research-use KPV 10mg vial is approved, safe or effective for human inflammatory conditions, gut health, autoimmune support, pain, skin treatment or therapeutic use.
KPV has also appeared in intestinal epithelial and barrier-pathway research. For product copy, this should be framed as epithelial barrier and inflammatory pathway research only, not as a claim about gut healing, IBD treatment, digestive support or human use.
| Research Area | KPV |
| Main research category | Alpha-MSH-derived tripeptide research |
| Sequence | Lys-Pro-Val |
| Peptide length | Three amino acids |
| Parent peptide context | Alpha-melanocyte-stimulating hormone, also known as alpha-MSH |
| Common pathway interest | Cytokine signalling, melanocortin-related signalling and inflammatory pathway models |
| Barrier research interest | Epithelial barrier and intestinal cell model research |
| Immune pathway interest | Inflammatory signalling and cellular response pathway models |
| Evidence limitation | Research context does not make KPV products approved for human use |
| Product limitation | Research use only, not approved for human or animal use |
| Feature | KPV | Alpha-MSH |
| Research class | Short tripeptide research peptide | Larger melanocortin peptide hormone research context |
| Sequence focus | Lys-Pro-Val | Full alpha-MSH sequence context |
| Main research interest | C-terminal tripeptide and inflammatory pathway models | Melanocortin receptor, pigmentation and endocrine pathway research |
| Common pathway overlap | Melanocortin-related and inflammatory pathway research | Melanocortin signalling and pigmentation pathway research |
| Common SEO risk | Anti-inflammatory, gut health and autoimmune claims | Tanning, pigmentation and hormone claims |
| Safer positioning | Alpha-MSH-derived tripeptide research | Melanocortin pathway research context |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | KPV | BPC-157 |
| Research class | Alpha-MSH-derived tripeptide | Stable gastric pentadecapeptide research peptide |
| Peptide length | 3 amino acids | 15 amino acids |
| Main research focus | Cytokine, epithelial barrier and inflammatory pathway research | Cytoprotection, angiogenesis and gastric peptide pathway research |
| Common research overlap | Barrier and tissue-response pathway models | Tissue-response and gastrointestinal pathway models |
| Common SEO risk | Gut healing, inflammation and autoimmune claims | Injury recovery, tendon repair and gut-healing claims |
| Safer positioning | Inflammatory pathway research peptide | Gastric pentadecapeptide research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | KPV | ARA-290 / Cibinetide |
| Research class | Alpha-MSH-derived tripeptide | Erythropoietin-derived peptide research compound |
| Peptide length | 3 amino acids | 11 amino acids |
| Main pathway interest | Melanocortin-related and inflammatory pathway research | Innate repair receptor, EPOR/CD131 and small nerve fibre pathway research |
| Common research overlap | Cytokine and inflammatory pathway models | Inflammatory and tissue-response pathway models |
| Common SEO risk | Anti-inflammatory, gut health and immune claims | Neuropathy, pain and tissue repair claims |
| Safer positioning | KPV inflammatory pathway research | Innate repair receptor pathway research |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | KPV | TB-500 |
| Research class | Alpha-MSH-derived tripeptide | Thymosin beta-4 fragment research peptide |
| Main pathway interest | Cytokine, epithelial barrier and inflammatory pathway models | Actin, cell migration and tissue-remodelling pathway research |
| Peptide length | 3 amino acids | Commonly discussed as a heptapeptide fragment |
| Common research overlap | Tissue-response and cellular signalling research | Tissue-response and cell migration research |
| Common SEO risk | Anti-inflammatory and gut health claims | Injury recovery, sports recovery and tissue repair claims |
| Safer positioning | Melanocortin-related inflammatory pathway research | Thymosin beta-4 fragment research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Product | Safer Research Positioning |
| KPV 10mg | Alpha-MSH-derived tripeptide and inflammatory pathway research |
| BPC-157 10mg | Stable gastric pentadecapeptide and cytoprotection pathway research |
| TB-500 10mg | Thymosin beta-4 fragment, actin and cell migration pathway research |
| ARA-290 Cibinetide 10mg | Innate repair receptor and small nerve fibre pathway research |
| GHK-Cu 50mg / 100mg | Copper peptide and extracellular matrix pathway research |
| KLOW Peptide Blend 80mg | CoA-confirmed cellular signalling and tissue-response blend research |
These products should not be written as if they are interchangeable. KPV should be positioned around alpha-MSH-derived tripeptide, cytokine and inflammatory pathway research, not human anti-inflammatory treatment, gut healing, autoimmune support or recovery use.
| Common Online Claim | Safer Research-Use Wording |
| Anti-inflammatory | Studied in inflammatory pathway research models |
| Gut healing | Better framed as epithelial barrier and intestinal cell model research |
| IBD support | Not an approved or appropriate product claim |
| Autoimmune support | Not an approved or appropriate product claim |
| Pain relief | Not suitable for research-use product positioning |
| Skin healing | Better framed as cellular signalling or skin pathway research where supported by literature |
| Wound healing | Better framed as wound-response research models only |
| Immune support | Better framed as cytokine and immune signalling research |
| Recovery | Not an approved or appropriate product claim |
| Injectable peptide | Not suitable for research-use product positioning |
KPV 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for inflammation, gut health, IBD, autoimmune conditions, pain relief, immune support, skin repair, wound healing, injury recovery, tissue repair, recovery, cosmetic use, topical use, injection, supplementation or therapeutic use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for KPV 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, salt form, acetate status, pH conditions, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities, treatment quantities, topical quantities or administration schedules.
Before handling KPV 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised KPV peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is Lys-Pro-Val / KPV |
| Salt form or acetate confirmation | Supports accurate concentration and handling records |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity, sequence and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up or salt-form confusion | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from KLOW blends, BPC-157, ARA-290 and other inflammatory pathway research products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Sequence tracking | Record KPV / Lys-Pro-Val identity where documented |
| Salt-form tracking | Record acetate or supplier-specific form where documented |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules, gut health protocols, anti-inflammatory protocols, treatment schedules or administration guidance.
KPV 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is KPV |
| Sequence confirmation | Lys-Pro-Val where documented |
| Salt form | Supplier-specific salt form or acetate status, where documented |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
| Compliance check | Confirmation that no inflammation treatment, gut health, autoimmune, topical or injection wording is attached to the material |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or human-use claims are mixed into research-use product pages.
Because KPV is commonly discussed online in relation to inflammation, gut health, barrier function, autoimmune conditions and skin pathways, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, topical use, disease management or treatment use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify the product is KPV |
| Confirm the Lys-Pro-Val sequence where documented | Supports accurate product identification |
| Confirm salt form where documented | Supports correct research calculations |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Keep inflammatory pathway research separate from human treatment claims | Avoids unsafe or misleading product positioning |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as an anti-inflammatory product | Creates human-use and therapeutic claim risk |
| Never make gut-healing or IBD claims | Not suitable for a research-use product page |
| Never make autoimmune support claims | Not an approved or appropriate product claim |
| Never make pain relief claims | Not an approved or appropriate product claim |
| Never make wound-healing or skin-treatment claims | Not suitable for research-use material |
| Never imply cytokine pathway research equals human therapeutic benefit | Research context is not a product-use claim |
| Never copy treatment protocols from social media | They may be unsafe, inaccurate or non-compliant |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
The table below is for concentration planning only. It does not represent dosage, injection quantity, treatment quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example, treatment example, injection example, topical-use example or administration instruction.
KPV is a tripeptide research peptide made from lysine, proline and valine. It is commonly discussed as the C-terminal tripeptide sequence associated with alpha-MSH-related pathway research.
Yes. KPV is a tripeptide, meaning it is made from three amino acid components: lysine, proline and valine.
KPV stands for Lys-Pro-Val, which refers to the three amino acids lysine, proline and valine.
KPV is commonly studied in relation to alpha-MSH-derived tripeptide research, melanocortin-related signalling, cytokine pathway models, epithelial barrier research and inflammatory pathway models. A PubMed Central review discusses KPV as the C-terminal tripeptide associated with alpha-MSH-related inflammatory pathway activity.
No. This research product is not approved or supplied for inflammation, gut health, IBD, autoimmune conditions, immune support, pain relief, wound healing, topical use, injection or human administration. It should be described only as a laboratory research product.
No. KPV is a short tripeptide associated with the C-terminal sequence of alpha-MSH. Alpha-MSH is a larger melanocortin peptide context. They should not be treated as identical products.
No. KPV is an alpha-MSH-derived tripeptide research peptide. BPC-157 is a stable gastric pentadecapeptide research peptide. They may appear in some overlapping pathway discussions, but they are chemically different products.
Not necessarily. KPV is a specific tripeptide. KLOW Peptide Blend is a blend product, and its components must be confirmed by the Certificate of Analysis before making any component-specific statements.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem MSH 11-13 compound profile | Useful background on KPV-related identity and molecular formula. |
| PubChem KPV acetate compound profile | Useful background if the product CoA confirms an acetate salt form. |
KPV 10mg for qualified laboratory research only. Not for human or veterinary use.
